SNPMiner Trials (Home Page)
Report for Mutation A27L
 Developed by Shray Alag, 2020.
SNP Clinical Trial Gene 
There is one clinical trial. 
Clinical Trials
      This phase I/II study is directed at evaluating safety and immunogenicity of a melanoma
      peptide vaccine in combination or not with Dacarbazine administration in melanoma patients
    
NCT00559026  Melanoma  Biological: Melan-A  Other: Melan-A plus Dacarbazine 
injections of Melan-A: 26-35 (A27L) and gp100:
      209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. --- A27L --- 
  Primary Outcomes 
 Measure: Assessment of safety by evaluating local and systemic adverse reactions during the trial. Assessment of the vaccine-specific cellular immune responses
 Time: one year
  Secondary Outcomes 
 Measure: Assessment of relapse-free survival and overall survival calculated from the time of the first chemotherapy/vaccine injection. Evaluation by microarray analysis of the gene expression profiles of patients PBMC 24 h after DTIC administration.
 Time: two years
HPO Nodes
Genes 15
HRAS  MITF  CDKN2A  BRAF  NRAS  NRAS  WRN  CDKN2A  CXCR4  BAP1  POLH  CDK4  ERCC3  XPC  MC1R   hr>